Summary & Overview
HCPCS Level II J2781: Pegcetacoplan Intravitreal Injection, 1 mg
HCPCS Level II code J2781 denotes an intravitreal injection of pegcetacoplan, 1 mg. As a drug-specific HCPCS Level II code for ophthalmic intravitreal therapy, J2781 matters nationally for billing, coverage determination, and specialty pharmacy distribution tied to retinal disease management. Its use captures drug acquisition and utilization for intravitreal pegcetacoplan therapy and supports claims processing and reimbursement for clinicians and facilities providing the injection.
Key payers included in the coverage landscape are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for intravitreal pegcetacoplan, common sites of service, and the payer mix relevant to national billing considerations. The publication outlines benchmark topics including standard billing practice for HCPCS Level II drug codes, common modifier usage patterns, and how payers typically approach coverage and prior authorization for intravitreal pharmacotherapies.
The report also summarizes policy and coding updates that affect HCPCS drug reporting, describes service line implications for ophthalmology clinics and outpatient surgical centers, and highlights data points readers can use for operational planning. Data not available in the input will be identified explicitly in the detailed sections.
Billing Code Overview
HCPCS Level II code J2781 represents an intravitreal injection of pegcetacoplan, 1 mg. This entry describes a single-dose administration of pegcetacoplan delivered directly into the vitreous cavity of the eye.
-
Service type: Intravitreal medication administration
-
Typical site of service: Ambulatory ophthalmology clinic or outpatient surgical setting
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) presenting for intravitreal therapy with pegcetacoplan. The patient has progressive central or paracentral vision loss documented on visual acuity testing and monitoring imaging (optical coherence tomography and fundus autofluorescence) showing enlarging areas of atrophy. Prior to injection there is a pre-procedure evaluation including informed consent, allergy review, medication reconciliation (antiplatelet/anticoagulant status), and measurement of visual acuity and intraocular pressure. The intravitreal injection of J2781 (pegcetacoplan, intravitreal, 1 mg) is performed in a procedure room or ambulatory surgery center under sterile technique: topical antisepsis with povidone-iodine, topical anesthesia, application of a lid speculum, and use of a calibrated needle to deliver the specified dose into the vitreous cavity. Post-injection care includes intraocular pressure check, topical antibiotic or anti-inflammatory drops per clinic protocol, documented post-procedure instructions, and scheduling of follow-up visits for monitoring efficacy and adverse effects (endophthalmitis, intraocular inflammation, elevated intraocular pressure). Documentation should include the drug name and dosage as J2781, lot number, expiration, injection site (right RT or left LT), procedure consent, and any applicable modifier(s) for billing and payer adjudication. Typical site of service is an ophthalmology clinic procedure room or ambulatory surgical center. Typical providers are retinal specialists (ophthalmology).
Coding Specifications
| Modifier | Description |
|---|